AVENUE THERAPEUTICS, INC. 8-K

What Happened

• Avenue Therapeutics, Inc. filed an 8-K reporting that on February 18, 2026 it entered an exclusive, worldwide License Agreement with Duke University to develop and commercialize certain patents and know‑how, including for ATX-04 (clenbuterol), aimed at treating lysosomal storage diseases.
• The company said it intends to advance ATX-04 into a late‑stage clinical development program, initially focusing on Pompe disease as an adjunct to enzyme replacement therapy (ERT). A press release announcing the agreement was issued February 23, 2026 (Exhibit 99.1).

Key Details

• Date of agreement: February 18, 2026; press release filed February 23, 2026.
• Scope: Exclusive, worldwide license to Duke patents and know‑how for development and commercialization of ATX‑04 and related products; Duke and other non‑profits retain non‑commercial research/education rights.
• Payments/financial terms: Company agreed to an upfront payment and reimbursement of certain patent expenses, plus development, regulatory and commercial milestone payments; it will pay a tiered low single‑digit royalty on future net sales of licensed products. (No dollar amounts were disclosed in the 8‑K.)
• Agreement terms: Includes customary diligence, termination rights for uncured material breach, insolvency-related events and specified patent challenges, and continues on a product‑by‑product and country‑by‑country basis while royalties are owed.

Why It Matters

• For investors, this gives Avenue explicit rights to develop and commercialize ATX‑04, advancing the company from earlier-stage ownership of the asset toward planned late‑stage clinical work targeted at Pompe disease.
• Financial implications include upfront and milestone payment obligations and future royalty payments, but the filing does not disclose dollar amounts, so the size and timing of cash obligations and potential revenue remain uncertain.
• The deal may materially affect Avenue’s clinical and commercial strategy; investors should watch for the company’s planned filings of the full License Agreement, details on development timelines, and any subsequent disclosures about study design, costs, and milestone specifics.